Company intelligence / Profile preview

Mosanna Therapeutics

Basel, Basel-City, Switzerlandmosanna.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Mosanna Therapeutics’ lead candidate, MOS-118, is being developed as a pharmacologic therapy for metabolic obstructive sleep apnea. The company recently announced seed extension financing to complete preparations for entering clinical trials. No clinical results have been reported yet as they are preclinical.

Therapeutic areas: Metabolic Disorders
Modalities: small molecules (specifically, a medicinal nasal spray)
Industry: Biotech

Drug pipeline

1 asset

MOS-118

Unknown

Partnerships

Seed financing led by Forty51 Venturesuses contract research organizations for development work

Beyond the preview

Go deeper on Mosanna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mosanna Therapeutics.

Explore the full profile